Skip to main content

The Globe and Mail

Toronto man who fought for access to experimental drug succumbs to melanoma

Cancer patient Darcy Doherty, along with his wife Rebecca Cumming, is photographed at his home in Toronto, Ont. Wednesday, May 30/2012.

Kevin Van Paassen/Kevin Van Paassen/The Globe and

A Toronto man who fought to get access to an experimental cancer drug has died of melanoma.

Friends and family of Darcy Doherty, 48, battled drug giant Bristol-Myers Squibb for compassionate access to a new drug called BMS-936558, which is in early stages of development. The company declined the request arguing the drug was not yet ready even though early testing had shown promising results.

Drug companies do provide some compassionate access to experimental medicine but only on a case-by-case basis and usually later in the testing process. Mr Doherty's family waged a public campaign to push Bristol-Myers to back down. That included a petition with more than 190,000 signatures, an email campaign and several videos.

Story continues below advertisement

"Darcy was a very special person and we will miss him greatly," his wife, Rebecca Cumming, said in a statement.

"He remains an inspiration to our family and many others whose lives have been touched by cancer. "

First diagnosed in 2003, Mr Doherty received the devastating diagnosis that his cancer had metastasized to his lungs and brain in 2007.

His doctor gave him only a few months to live.

However, he soon joined a clinical trial for the immunotherapy drug, ipilimumab (now called Yervoy) and enjoyed over four more years of quality life with few side effects.

The effects of that drug lessened by the end of 2011 and Mr Doherty was hoping the new BMS drug would be effective.

"I want to thank all the people who supported our family through this struggle over the past weeks and months by sending us their warm wishes, love and prayers, including everyone who signed our petition and followed us on Facebook," Ms Cumming added.

Story continues below advertisement

"We always remained hopeful that BMS would change its mind and Darcy would have another miracle. Sadly, that did not happen."

Report an error Licensing Options
About the Author
European Correspondent

Paul Waldie has been an award-winning journalist with The Globe and Mail for more than 10 years. He has won three National Newspaper Awards for business coverage and been nominated for a Michener Award for meritorious public service journalism. He has also won a Sports Media Canada award for sports writing and authored a best-selling biography of the McCain family. More


The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

Please note that our commenting partner Civil Comments is closing down. As such we will be implementing a new commenting partner in the coming weeks. As of December 20th, 2017 we will be shutting down commenting on all article pages across our site while we do the maintenance and updates. We understand that commenting is important to our audience and hope to have a technical solution in place January 2018.

Discussion loading… ✨